AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$TXG

Saxonov Serge sold $1.2M of TXG

Saxonov Serge (Chief Executive Officer) sold 18,545 shares of 10x Genomics, Inc. (TXG) at $63.02 ($1.17M total) on 2026-08-24.

Original reporting
SEC EDGAR · Saxonov Serge
Published Aug 26, 2026, 8:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TXG
Bearish
medium confidence
Mentioned
$TXG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TXGBearishLow
01

Why it matters

The sale reduces the CEO's ownership, which may be viewed negatively by investors.

02

Market read

Insider sell by a CEO can affect short-term sentiment and price action.

03

Timing

post-market 2026-08-24

Relevance 6/10Novelty 7/10Timing: post-market 2026-08-24

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$TXGBearishMedium confidence
Context

CEO Serge Saxonov sold 18,545 shares for $1.17M, reducing his stake to 1,085,835 shares.

Expected impact

Possible modest dip in share price over next few days.

Evidence & confidence

Large insider sell by CEO, $1.2M transaction, could be interpreted as lack of confidence.

Key entities

  • Company
    10x Genomics, Inc.

    Biotech company whose ticker is TXG.

  • Person
    Saxonov Serge

    CEO of 10x Genomics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TXG insider trading history →

Related articles

SEP 3
$TXGMed

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.

tradingview.com3 min
AUG 18
$TXGMed

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

10x Genomics (NASDAQ:TXG) reported Q2 revenue of $151m, including a $1.6m Takara settlement; excluding it, revenue was $149.4m, up 3% YoY. Atera booked orders already exceed planned 2026 shipments (~40 units). Cash rose to $552m and gross margin to 74%. Full-year revenue guidance raised to $610m-$630m; instrument revenue fell 47% YoY.

yahoo.com3 min
AUG 14
$TXGMedAI 9/10

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.

fool.com10 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min